Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which...

Area of Science:

• Clinical Trial Design
• Biostatistics in Oncology
• Drug Development Strategy

Background:

• Designing oncology clinical programs is complex, with high failure rates in Phase 2 and Phase 3 trials over the past decade.
• Standard clinical trial approaches have demonstrated limited success in oncology drug development.
• Improving development strategies through innovative statistical methods is crucial for drug development.

Purpose of the Study:

• To evaluate and compare hypothetical oncology clinical programs using various Phase 2 and Phase 3 study design combinations.
• To assess the impact of adaptive designs on the probability of clinical program success and expected net present value (eNPV).
• To identify optimal development strategies for oncology drug development.

Main Methods:

• Simulation of eight Phase 2/Phase 3 oncology development programs using combinations of five Phase 2 and three Phase 3 study designs.
• Comparison of simulated programs based on the probability of clinical program success and expected net present value (eNPV).
• Evaluation of adaptive designs, including response adaptive randomization, and group sequential designs.

Main Results:

• Development strategies incorporating adaptive designs showed robust improvement in eNPV compared to standard approaches.
• A three-arm response adaptive randomization design in Phase 2 combined with a group sequential design with 5 analyses in Phase 3 yielded the highest eNPV.
• The study identified specific design combinations that enhance the probability of clinical program success in oncology.

Conclusions:

• Innovative statistical methods, particularly adaptive designs, can significantly improve the efficiency and success rates of oncology clinical programs.
• Response adaptive randomization in Phase 2 and group sequential designs in Phase 3 represent superior development strategies.
• The findings provide valuable insights for optimizing oncology drug development pathways.